From the Molecular Genetics Section, Department of Pediatrics (A.F., M. Wijers, J.C.W., D.D., M.S., N.H., N.K., M.H.H., M. Westerterp, J.A.K., B.v.d.S).
University Medical Center Groningen, University of Groningen, The Netherlands; PolyQuant GmbH, Bad Abbach, Germany (H.K.).
Circ Res. 2018 Jun 8;122(12):1648-1660. doi: 10.1161/CIRCRESAHA.117.312004. Epub 2018 Mar 15.
COMMD (copper metabolism MURR1 domain)-containing proteins are a part of the CCC (COMMD-CCDC22 [coiled-coil domain containing 22]-CCDC93 [coiled-coil domain containing 93]) complex facilitating endosomal trafficking of cell surface receptors. Hepatic COMMD1 inactivation decreases CCDC22 and CCDC93 protein levels, impairs the recycling of the LDLR (low-density lipoprotein receptor), and increases plasma low-density lipoprotein cholesterol levels in mice. However, whether any of the other COMMD members function similarly as COMMD1 and whether perturbation in the CCC complex promotes atherogenesis remain unclear.
The main aim of this study is to unravel the contribution of evolutionarily conserved COMMD proteins to plasma lipoprotein levels and atherogenesis.
Using liver-specific , , or knockout mice, we investigated the relation between the COMMD proteins in the regulation of plasma cholesterol levels. Combining biochemical and quantitative targeted proteomic approaches, we found that hepatic COMMD1, COMMD6, or COMMD9 deficiency resulted in massive reduction in the protein levels of all 10 COMMDs. This decrease in COMMD protein levels coincided with destabilizing of the core (CCDC22, CCDC93, and chromosome 16 open reading frame 62 [C16orf62]) of the CCC complex, reduced cell surface levels of LDLR and LRP1 (LDLR-related protein 1), followed by increased plasma low-density lipoprotein cholesterol levels. To assess the direct contribution of the CCC core in the regulation of plasma cholesterol levels, was deleted in mouse livers via CRISPR/Cas9-mediated somatic gene editing. CCDC22 deficiency also destabilized the complete CCC complex and resulted in elevated plasma low-density lipoprotein cholesterol levels. Finally, we found that hepatic disruption of the CCC complex exacerbates dyslipidemia and atherosclerosis in ApoE3*Leiden mice.
Collectively, these findings demonstrate a strong interrelationship between COMMD proteins and the core of the CCC complex in endosomal LDLR trafficking. Hepatic disruption of either of these CCC components causes hypercholesterolemia and exacerbates atherosclerosis. Our results indicate that not only COMMD1 but all other COMMDs and CCC components may be potential targets for modulating plasma lipid levels in humans.
含有 COMMD(铜代谢 MURR1 结构域)蛋白的复合物是 CCC(COMMD-CCDC22[卷曲螺旋域包含 22]-CCDC93[卷曲螺旋域包含 93])复合物的一部分,该复合物有助于细胞表面受体的内体运输。肝 COMMD1 失活会降低 CCDC22 和 CCDC93 蛋白水平,损害 LDLR(低密度脂蛋白受体)的再循环,并增加小鼠血浆中低密度脂蛋白胆固醇水平。然而,是否有其他任何 COMMD 成员与 COMMD1 相似地发挥作用,以及 CCC 复合物的扰动是否会促进动脉粥样硬化的发生仍不清楚。
本研究的主要目的是阐明进化保守的 COMMD 蛋白在调节血浆脂蛋白水平和动脉粥样硬化中的作用。
使用肝特异性 、 或 敲除小鼠,我们研究了 COMMD 蛋白在调节血浆胆固醇水平中的关系。通过生化和定量靶向蛋白质组学方法相结合,我们发现肝 COMMD1、COMMD6 或 COMMD9 缺乏会导致所有 10 种 COMMD 蛋白的大量减少。这种 COMMD 蛋白水平的降低与 CCC 核心(CCDC22、CCDC93 和染色体 16 开放阅读框 62 [C16orf62])的不稳定一致,导致 LDLR 和 LRP1(LDLR 相关蛋白 1)的细胞表面水平降低,随后血浆中低密度脂蛋白胆固醇水平升高。为了评估 CCC 核心在调节血浆胆固醇水平中的直接作用,我们通过 CRISPR/Cas9 介导的体细胞基因编辑在小鼠肝脏中删除 。CCDC22 缺乏也会使完整的 CCC 复合物不稳定,并导致血浆中低密度脂蛋白胆固醇水平升高。最后,我们发现肝脏 CCC 复合物的破坏会加剧 ApoE3*Leiden 小鼠的血脂异常和动脉粥样硬化。
总之,这些发现表明 COMMD 蛋白与 CCC 复合物的核心在 LDLR 内体运输中具有很强的相互关系。这些 CCC 成分中的任何一种在肝脏中的破坏都会导致高胆固醇血症并加剧动脉粥样硬化。我们的研究结果表明,不仅 COMMD1,而且所有其他 COMMD 和 CCC 成分都可能是调节人类血浆脂质水平的潜在靶点。